Edoxaban Avansor
Direct oral anticoagulant (DOAC) – Factor Xa inhibitor for stroke prevention and blood clot treatment
Edoxaban Avansor is a prescription anticoagulant medication containing the active substance edoxaban tosilate hydrate. It belongs to a class of medicines known as direct oral anticoagulants (DOACs) that work by inhibiting factor Xa, a key enzyme in the blood clotting cascade. The 15 mg strength is primarily used as a reduced dose for patients who require dose adjustment due to specific clinical factors.
Quick Facts
Key Takeaways
- Edoxaban Avansor is a direct oral anticoagulant (DOAC) that prevents blood clots by directly inhibiting factor Xa in the coagulation cascade.
- The 15 mg tablet is a reduced-dose formulation used for patients with specific dose-reduction criteria such as low body weight, moderate-to-severe renal impairment, or concomitant P-glycoprotein inhibitor use.
- Taken once daily with or without food, offering predictable anticoagulation without routine blood monitoring – unlike warfarin.
- Bleeding is the most significant risk; patients should watch for signs such as unusual bruising, blood in urine or stools, and prolonged nosebleeds, and seek immediate medical attention for any major bleeding event.
- Never stop taking Edoxaban Avansor without consulting your doctor, as abrupt discontinuation increases the risk of stroke and blood clots.
What Is Edoxaban Avansor and What Is It Used For?
Edoxaban Avansor belongs to a group of medicines called direct oral anticoagulants, sometimes referred to as novel oral anticoagulants (NOACs) or DOACs. Its active substance, edoxaban tosilate hydrate, is a highly selective, direct and reversible inhibitor of factor Xa, a serine protease that plays a central role in the blood coagulation cascade. By blocking factor Xa, the medicine reduces the body's ability to form harmful blood clots.
The coagulation cascade is a complex series of enzymatic reactions that ultimately leads to the formation of fibrin, the protein mesh that stabilises blood clots. Factor Xa sits at a critical junction in this cascade, at the point where the intrinsic and extrinsic pathways converge. By inhibiting factor Xa directly, edoxaban effectively reduces thrombin generation – thrombin being the enzyme that converts fibrinogen to fibrin. This mechanism provides potent and predictable anticoagulant activity.
Edoxaban Avansor is approved by the European Medicines Agency (EMA) and is prescribed for two primary clinical indications. The first is the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), heart failure, age 75 years or older, diabetes mellitus, or hypertension. Atrial fibrillation causes the upper chambers of the heart to beat irregularly, which can lead to blood pooling and clot formation; these clots may then travel to the brain and cause a stroke.
The second major indication is the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent DVT and PE in adults. DVT occurs when a blood clot forms in a deep vein, usually in the leg, while PE occurs when a fragment of such a clot breaks off and lodges in the pulmonary arteries. Both conditions can be life-threatening and require effective anticoagulation therapy.
The 15 mg strength of Edoxaban Avansor is specifically designed as a reduced dose for patients who meet certain criteria. According to the EMA-approved prescribing information and the landmark ENGAGE AF-TIMI 48 and Hokusai-VTE clinical trials, dose reduction to 15 mg once daily (from the standard 30 mg reduced dose) is recommended for patients with moderate-to-severe renal impairment (creatinine clearance 15–50 mL/min), low body weight (60 kg or less), or concomitant use of potent P-glycoprotein (P-gp) inhibitors such as cyclosporine, dronedarone, erythromycin, or ketoconazole.
What Should You Know Before Taking Edoxaban Avansor?
Before prescribing Edoxaban Avansor, your healthcare provider will conduct a thorough assessment of your medical history, current medications, kidney function, and overall bleeding risk. Anticoagulant therapy requires careful patient selection, and there are important contraindications, warnings, and precautions that must be considered.
Contraindications
You must not take Edoxaban Avansor if any of the following apply to you:
- Hypersensitivity to edoxaban tosilate hydrate or any of the excipients listed in the tablet composition.
- Clinically significant active bleeding – this includes gastrointestinal haemorrhage, intracranial bleeding, or any other active major bleeding at the time of starting treatment.
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including patients with cirrhotic patients classified as Child-Pugh B or C.
- Uncontrolled severe hypertension that significantly increases the risk of intracranial bleeding.
- Conditions with a significant risk of major bleeding, such as current or recent gastrointestinal ulceration, malignant neoplasms at high bleeding risk, recent brain or spinal injury or surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Concomitant treatment with any other anticoagulant agent, such as unfractionated heparin, low-molecular-weight heparins (enoxaparin, dalteparin), heparin derivatives (fondaparinux), oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban), except under specific circumstances of switching anticoagulant therapy or when unfractionated heparin is given at doses necessary to maintain a patent central venous or arterial catheter.
- Pregnancy and breastfeeding – Edoxaban Avansor should not be used during pregnancy or breastfeeding due to potential risks to the foetus and infant (see Pregnancy and Breastfeeding section below).
Warnings and Precautions
Several important warnings and precautions apply to all patients taking Edoxaban Avansor. Discuss these with your doctor before starting treatment:
Like all anticoagulants, Edoxaban Avansor increases the risk of bleeding, which can be serious or fatal. You should be carefully monitored for signs and symptoms of bleeding, especially during the first year of treatment and in patients with additional risk factors.
Haemorrhagic risk: Edoxaban Avansor should be used with caution in conditions with increased risk of bleeding. If severe haemorrhage occurs, treatment should be discontinued. In the ENGAGE AF-TIMI 48 trial, major bleeding occurred in approximately 2.75% of patients receiving edoxaban per year, compared with 3.43% with warfarin. Clinically relevant non-major bleeding occurred in approximately 8.67% per year.
Renal impairment: Kidney function must be assessed before starting treatment and should be periodically re-evaluated. Edoxaban exposure increases as renal function declines. Patients with creatinine clearance below 15 mL/min should not receive edoxaban, as clinical data are very limited in this population. Importantly, in the ENGAGE AF-TIMI 48 trial, patients with creatinine clearance above 95 mL/min had a higher rate of ischaemic stroke compared with warfarin, and edoxaban should only be used in such patients after careful evaluation of thromboembolic and bleeding risk.
Hepatic impairment: Patients with severe hepatic impairment (Child-Pugh C) should not take this medicine. Those with mild-to-moderate hepatic impairment (Child-Pugh A or B) should be treated with caution and have their liver function monitored. Edoxaban Avansor is contraindicated in hepatic disease associated with coagulopathy.
Mechanical heart valves: Edoxaban has not been studied in patients with mechanical prosthetic heart valves. Its use in this population is therefore not recommended due to potential lack of efficacy.
Haemodynamically unstable PE: Edoxaban should not be used as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may require thrombolysis or pulmonary embolectomy.
Surgery and invasive procedures: If surgery or other invasive procedures are required, Edoxaban Avansor should be discontinued at least 24 hours before the procedure. If the procedure cannot be delayed, the increased risk of bleeding should be weighed against the urgency of the intervention. Edoxaban should be restarted after the procedure as soon as adequate haemostasis has been established.
Pregnancy and Breastfeeding
Edoxaban Avansor is not recommended for use during pregnancy. Animal reproductive studies have shown that edoxaban crosses the placenta and may cause adverse effects on the developing foetus. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should use effective contraception during treatment with Edoxaban Avansor.
It is not known whether edoxaban or its metabolites are excreted in human breast milk. Animal data have shown excretion in milk. Therefore, breastfeeding is not recommended during treatment with this medicine. A decision must be made whether to discontinue breastfeeding or to discontinue the medicine, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
If you become pregnant while taking Edoxaban Avansor, contact your doctor immediately. Do not stop the medication on your own, as abrupt discontinuation can lead to life-threatening blood clots. Your doctor will discuss the safest approach for both you and your baby.
How Does Edoxaban Avansor Interact with Other Drugs?
Drug interactions with Edoxaban Avansor are clinically important because they can either increase the risk of bleeding (by raising edoxaban plasma concentrations) or reduce the drug's effectiveness in preventing blood clots (by lowering its concentrations). The primary interaction pathway involves P-glycoprotein (P-gp), a membrane transporter that influences the absorption and elimination of edoxaban. Unlike some other DOACs, edoxaban has minimal cytochrome P450 (CYP) metabolism, so CYP-based interactions are generally less significant.
Your doctor and pharmacist need to know about all medications you are currently taking, including prescription medicines, over-the-counter drugs, herbal supplements, and vitamins. Below is a summary of the most important drug interactions with Edoxaban Avansor.
Major Interactions
| Drug / Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Cyclosporine | Strong P-gp inhibitor; increases edoxaban levels by approximately 73% | Dose reduction to 15 mg once daily required |
| Dronedarone | Strong P-gp inhibitor; increases edoxaban levels by approximately 85% | Dose reduction to 15 mg once daily required |
| Ketoconazole | Strong P-gp inhibitor; increases edoxaban AUC by approximately 87% | Dose reduction to 15 mg once daily required |
| Erythromycin | P-gp inhibitor; increases edoxaban levels by approximately 85% | Dose reduction to 15 mg once daily required |
| Warfarin and other anticoagulants | Additive anticoagulant effect; substantially increased bleeding risk | Concomitant use contraindicated; switch protocols must be followed carefully |
| Rifampicin | Strong P-gp inducer; reduces edoxaban levels by approximately 34% | Avoid concomitant use; may reduce anticoagulant efficacy |
Moderate and Minor Interactions
| Drug / Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Aspirin (acetylsalicylic acid) | Increased bleeding risk due to additive antiplatelet and anticoagulant effects | Low-dose aspirin (≤100 mg/day) may be used with caution; higher doses should be avoided |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Increased bleeding risk, particularly gastrointestinal | Avoid chronic use; short-term use with monitoring may be acceptable |
| Clopidogrel, ticagrelor, prasugrel | Additive antiplatelet effect; increased bleeding risk | Use only when clinically essential; monitor closely for bleeding |
| Phenytoin, carbamazepine | P-gp inducers; may reduce edoxaban plasma levels | Monitor for reduced efficacy; consider alternative anticonvulsants |
| St John's Wort (Hypericum perforatum) | P-gp inducer; may reduce edoxaban effectiveness | Avoid concomitant use |
| SSRIs and SNRIs | May impair platelet function; modest increase in bleeding risk | Be aware of increased bleeding tendency; monitor for signs |
The above tables are not exhaustive. Additional P-gp inhibitors such as verapamil, quinidine, and amiodarone may modestly increase edoxaban levels but generally do not require dose adjustment. Proton pump inhibitors (PPIs), H2-receptor antagonists, and antacids do not significantly affect edoxaban pharmacokinetics. Always inform your healthcare provider about all supplements and medications, including herbal products, that you are taking.
What Is the Correct Dosage of Edoxaban Avansor?
The dosing of edoxaban is based on the clinical indication, the patient's kidney function, body weight, and concomitant medications. Edoxaban Avansor 15 mg represents the lowest available dose strength and is used when additional dose reduction beyond the standard 30 mg reduced dose is warranted. It is essential that the dose is determined and supervised by a healthcare professional.
Adults
For adults with non-valvular atrial fibrillation (NVAF), the standard dose of edoxaban is 60 mg once daily. A dose reduction to 30 mg once daily is required for patients with one or more of the following: creatinine clearance (CrCl) 15–50 mL/min, body weight ≤60 kg, or concomitant use of P-gp inhibitors (cyclosporine, dronedarone, erythromycin, or ketoconazole). In certain clinical scenarios where a patient already requires the 30 mg dose and also has an additional dose-reduction factor, the 15 mg dose may be considered based on individual clinical assessment.
NVAF – Stroke Prevention
Standard dose: Edoxaban 60 mg once daily
Reduced dose: Edoxaban 30 mg once daily (CrCl 15–50 mL/min, weight ≤60 kg, or concomitant P-gp inhibitor)
Further reduced dose: Edoxaban 15 mg once daily may be used in select patients based on clinical judgement
For the treatment of DVT and PE, edoxaban is administered following initial parenteral anticoagulation (typically with heparin or low-molecular-weight heparin) for at least 5 days. The standard dose is 60 mg once daily, with reduction to 30 mg once daily for patients meeting the criteria described above. Treatment duration depends on the clinical situation, risk of recurrence, and individual bleeding risk, typically ranging from 3 months to indefinite duration for recurrent VTE.
DVT / PE Treatment
Initial therapy: Parenteral anticoagulation for at least 5 days
Then: Edoxaban 60 mg once daily (or 30 mg with dose-reduction criteria)
Duration: Minimum 3 months; longer for recurrent VTE
Children and Adolescents
The safety and efficacy of edoxaban in children and adolescents below 18 years of age have not been established. No data are currently available to support use in paediatric patients, and Edoxaban Avansor is therefore not recommended for use in this age group. Paediatric anticoagulation should be managed with age-appropriate therapies under specialist supervision.
Elderly Patients
No dose adjustment is required solely based on age. However, elderly patients frequently have reduced renal function and lower body weight, both of which may independently trigger dose reduction criteria. In the ENGAGE AF-TIMI 48 trial, approximately 40% of enrolled patients were aged 75 years or older, and the efficacy and safety profile of edoxaban was consistent across age groups. Nonetheless, elderly patients should be monitored more frequently for signs of bleeding, and renal function should be reassessed periodically.
Missed Dose
If you forget to take a dose of Edoxaban Avansor, take it as soon as you remember on the same day. Do not take a double dose on the next day to make up for the forgotten dose. Simply continue with your normal once-daily schedule the following day. If you are unsure what to do, contact your doctor or pharmacist.
Edoxaban Avansor can be taken with or without food. Swallow the tablet whole with water. For patients who have difficulty swallowing, the tablet may be crushed and mixed with water or apple puree, and should be administered immediately. The crushed tablet can also be administered through a nasogastric tube in a small amount of water.
Overdose
Overdose with Edoxaban Avansor may lead to an increased risk of bleeding. There is no specific antidote for edoxaban, although andexanet alfa (a factor Xa inhibitor reversal agent) has been approved in some countries for the reversal of anticoagulation in life-threatening or uncontrolled bleeding. Edoxaban is not significantly removed by haemodialysis (approximately 9% clearance over 4 hours). Management of overdose is primarily supportive: discontinue the medication, apply local measures to control bleeding, and administer blood products (packed red blood cells, fresh frozen plasma, platelet concentrates) as clinically indicated.
Activated charcoal may reduce absorption if given within 2 hours of an oral overdose. In cases of life-threatening bleeding, consider the use of prothrombin complex concentrate (PCC) or activated prothrombin complex concentrate (aPCC), although clinical evidence for these reversal strategies with edoxaban specifically is limited. Contact your local poison control centre or emergency department immediately if overdose is suspected.
What Are the Side Effects of Edoxaban Avansor?
Like all medicines, Edoxaban Avansor can cause side effects, although not everybody gets them. The most frequently reported adverse reactions in clinical trials (ENGAGE AF-TIMI 48 and Hokusai-VTE) are related to the drug's primary pharmacological action of anticoagulation. It is important to distinguish between minor bleeding events, which are relatively common and usually manageable, and major bleeding events, which are less frequent but potentially life-threatening.
In clinical trials involving over 21,000 patients receiving edoxaban, the overall incidence of clinically relevant bleeding was lower than with warfarin. However, gastrointestinal bleeding was slightly more common with edoxaban in some analyses. The following side effect frequency grid summarises the adverse reactions reported in clinical trials, categorised by frequency according to the MedDRA convention.
Very Common
- Cutaneous soft tissue bleeding (bruising, skin haemorrhage, petechiae, ecchymosis)
Common
- Epistaxis (nosebleeds)
- Gastrointestinal haemorrhage (upper and lower GI bleeding, rectal bleeding, gingival bleeding)
- Haematuria (blood in urine – microscopic or macroscopic)
- Vaginal bleeding (menorrhagia, metrorrhagia)
- Anaemia (from chronic blood loss)
- Rash and pruritus (itching)
- Elevated liver transaminases (ALT, AST, GGT)
- Abdominal pain
- Dizziness and headache
Uncommon
- Intracranial haemorrhage (haemorrhagic stroke, subdural or subarachnoid haemorrhage)
- Intraocular haemorrhage (conjunctival, retinal, or vitreous bleeding)
- Haemoptysis (coughing up blood)
- Surgical site haemorrhage
- Hepatic haemorrhage
- Elevated bilirubin and alkaline phosphatase
- Urticaria (hives)
- Thrombocytopenia
- Nausea
Rare
- Anaphylactic reaction and allergic oedema
- Retroperitoneal haemorrhage
- Intramuscular haemorrhage (with compartment syndrome)
- Pericardial haemorrhage
- Adrenal haemorrhage
- Intra-articular haemorrhage
Contact your doctor or go to the nearest emergency department immediately if you experience: unexplained severe or prolonged bleeding, blood in your vomit or stools (or black, tarry stools), coughing up blood, severe headache of sudden onset, sudden weakness or numbness on one side of the body, sudden vision changes, or signs of severe allergic reaction (difficulty breathing, swelling of face, lips, tongue or throat).
It is important to note that the risk of bleeding can be influenced by many factors, including age, body weight, kidney function, concomitant medications (especially antiplatelet agents and NSAIDs), and underlying medical conditions. Your doctor will carefully balance the benefit of preventing blood clots against the risk of bleeding when prescribing Edoxaban Avansor. If you experience any side effect that bothers you or does not go away, discuss it with your healthcare provider.
Post-marketing surveillance has identified additional rare adverse events. These include cases of immune thrombocytopenia and skin reactions. As with all relatively new medicines, ongoing pharmacovigilance continues to characterise the safety profile of edoxaban. Patients and healthcare professionals are encouraged to report suspected adverse reactions to their national pharmacovigilance authority.
How Should You Store Edoxaban Avansor?
Proper storage of Edoxaban Avansor is important to ensure the medication remains effective and safe throughout its shelf life. Film-coated tablets should be stored in their original blister packaging until the time of use, as this protects them from moisture and light degradation.
Store the tablets at a temperature not exceeding 30°C (86°F). Do not refrigerate or freeze. Keep the medicine in a dry place, away from direct sunlight, heat sources, and excessive humidity. Bathrooms and kitchens are generally not ideal storage locations due to fluctuating temperature and humidity levels.
As with all medications, Edoxaban Avansor must be kept out of the reach and sight of children. Accidental ingestion of an anticoagulant by a child is a medical emergency and requires immediate medical attention. Store the medicine in a secure location, ideally in a locked medicine cabinet.
Do not use this medicine after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of that month. Do not dispose of medicines in household waste or via wastewater. Ask your pharmacist about proper disposal methods in accordance with local environmental regulations. Proper pharmaceutical waste disposal helps to protect the environment.
What Does Edoxaban Avansor Contain?
Understanding the full composition of your medication is important, particularly for patients with known allergies or intolerances to specific excipients. Below is the detailed composition of Edoxaban Avansor 15 mg film-coated tablets.
Active substance: Each film-coated tablet contains edoxaban tosilate monohydrate, equivalent to 15 mg of edoxaban. Edoxaban tosilate is the salt form of the active molecule, chosen for its favourable pharmaceutical properties including stability and bioavailability.
Tablet core excipients: The tablet core typically contains mannitol (a sugar alcohol used as a filler and diluent), pregelatinised starch (serving as both a binder and disintegrant to facilitate tablet dissolution), crospovidone (a superdisintegrant that accelerates tablet break-up upon contact with gastrointestinal fluids), hydroxypropylcellulose (a binder that helps hold the tablet together), and magnesium stearate (a lubricant that prevents the tablet from sticking to manufacturing equipment during compression).
Film coating: The film coating of the tablet contains hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171, a white pigment), talc (a glidant and anti-tacking agent), and iron oxide pigments for colouration. The film coat serves to protect the tablet core, mask any bitter taste, improve swallowability, and provide a distinctive appearance for product identification.
The Edoxaban Avansor 15 mg tablet is available as a round, film-coated tablet that may be distinguished from other edoxaban dose strengths by its colour, size, and debossing. The specific appearance may vary by manufacturer batch, but each tablet is clearly marked for identification purposes.
This medicine does not contain lactose, gluten, or peanut-derived ingredients. However, if you have known hypersensitivity to any excipient listed above, inform your doctor or pharmacist before starting treatment. Mannitol may have a mild laxative effect in sensitive individuals.
Frequently Asked Questions About Edoxaban Avansor
Edoxaban Avansor and Lixiana (known as Savaysa in some countries) both contain the same active substance, edoxaban tosilate hydrate, and work in exactly the same way by inhibiting factor Xa. The difference is primarily in the brand name, manufacturer, and potentially the available strengths and excipients. Lixiana is the original reference product manufactured by Daiichi Sankyo, available in 15 mg, 30 mg, and 60 mg strengths. Edoxaban Avansor is available in the 15 mg strength. Your doctor will prescribe the formulation and dose that is most appropriate for your clinical situation. Bioequivalence must be demonstrated before a product is approved, meaning the active substance behaves the same way in the body regardless of brand.
While there is no absolute contraindication to consuming alcohol with edoxaban, moderation is strongly advised. Alcohol can affect liver function and may impair platelet function, both of which could increase your risk of bleeding. Heavy alcohol consumption can also affect your overall health and may interact with other medications you may be taking. The EMA and BNF recommend avoiding excessive alcohol intake while on anticoagulant therapy. As a general guideline, limit alcohol to no more than 1–2 standard drinks per day, and discuss your specific situation with your doctor.
Unlike warfarin, which requires regular INR monitoring to ensure the blood is within the desired therapeutic range, edoxaban generally does not require routine coagulation monitoring. This is one of the key advantages of direct oral anticoagulants. However, your doctor may order periodic blood tests to check your kidney function (creatinine and creatinine clearance), as renal impairment affects edoxaban levels and may necessitate dose adjustments. Liver function tests and a complete blood count may also be checked periodically to monitor for anaemia or other changes. Additionally, anti-factor Xa activity assays can be performed in specific clinical situations (such as overdose, emergency surgery, or suspected non-compliance) to estimate the anticoagulant effect of edoxaban.
In the event of emergency surgery or an urgent invasive procedure, inform the surgical team immediately that you are taking Edoxaban Avansor. The last dose timing is crucial information. Edoxaban has a half-life of approximately 10–14 hours, so anticoagulant activity is substantially reduced 24 hours after the last dose. For emergency situations where surgery cannot wait, the surgical team may use reversal agents such as andexanet alfa (where available) or prothrombin complex concentrate (PCC). For planned surgeries, your doctor will typically advise stopping Edoxaban Avansor at least 24 hours before the procedure (longer for procedures with high bleeding risk or in patients with reduced kidney function) and will provide specific instructions on when to restart the medication.
Edoxaban can be used in patients with mild-to-moderate renal impairment, but dose adjustment is essential. Approximately 50% of edoxaban is eliminated by the kidneys, so reduced renal function leads to higher drug levels. For patients with creatinine clearance (CrCl) of 15–50 mL/min, the dose should be reduced. Patients with CrCl below 15 mL/min should not use edoxaban due to very limited clinical data. Additionally, patients with CrCl above 95 mL/min should only receive edoxaban after careful evaluation, as higher CrCl was associated with increased stroke rates compared with warfarin in the ENGAGE AF-TIMI 48 trial. Your doctor will check your kidney function before starting treatment and at regular intervals thereafter.
Yes, switching from warfarin to edoxaban is possible and is done routinely in clinical practice. The standard protocol is to discontinue warfarin and start Edoxaban Avansor once the International Normalised Ratio (INR) falls to 2.5 or below. This ensures that the anticoagulant effect of warfarin has diminished sufficiently before edoxaban takes over. Do not take both medications simultaneously (except during the brief switching period under medical supervision), as the combined anticoagulant effect could substantially increase bleeding risk. Your doctor will provide specific instructions tailored to your situation.
Edoxaban Avansor has a rapid onset of action. Peak plasma concentrations are reached within 1 to 2 hours after oral administration, at which point significant anticoagulant activity is already present. This is substantially faster than warfarin, which typically takes 3 to 5 days to reach its full therapeutic effect. The rapid onset is one of the clinical advantages of DOACs like edoxaban, particularly in the treatment of DVT and PE (although initial parenteral anticoagulation for at least 5 days is still required before transitioning to oral edoxaban for VTE treatment).
References
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907
- Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. New England Journal of Medicine. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638
- European Medicines Agency. Edoxaban – Summary of Product Characteristics. EMA/CHMP. Last updated 2024. Available at: www.ema.europa.eu
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405
- NICE / British National Formulary. Edoxaban tosilate. BNF. Available at: bnf.nice.org.uk
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization; 2023.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051
Editorial Team
Written by iMedic Medical Editorial Team – specialists in clinical pharmacology, haematology, and cardiovascular medicine. All content is based on current evidence-based guidelines (ESC, EMA, BNF, WHO).
Reviewed by iMedic Medical Review Board – independent physicians who verify medical accuracy, guideline adherence, and clinical relevance. No conflicts of interest. No pharmaceutical funding.
This article follows the iMedic Editorial Standards for evidence-based medical information. Our team includes licensed medical professionals with expertise in anticoagulation therapy, clinical pharmacology, and internal medicine. For questions about this content, contact our editorial team.